^
+ Follow ANGIOTENSIN Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 416475
                    [Title] => Heart specialists welcome ARB trial
                    [Summary] => Local heart specialists welcomed the results of a landmark trial showing that the angiotensin receptor blocker (ARB) telmisartan is as effective as, and better tolerated than, the gold standard angiotensin-converting enzyme (ACE) inhibitor ramipril in reducing the risk of heart attack, stroke and hospitalization for congestive heart failure in high-risk patients.
                    [DatePublished] => 2008-11-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 140669
                    [Title] => Cardiovascular study underway
                    [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. 


The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan.

Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies.
[DatePublished] => 2001-11-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 134000 [Title] => Study centers in 40 countries involved in heart pr [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.
[DatePublished] => 2001-09-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
ANGIOTENSIN
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 416475
                    [Title] => Heart specialists welcome ARB trial
                    [Summary] => Local heart specialists welcomed the results of a landmark trial showing that the angiotensin receptor blocker (ARB) telmisartan is as effective as, and better tolerated than, the gold standard angiotensin-converting enzyme (ACE) inhibitor ramipril in reducing the risk of heart attack, stroke and hospitalization for congestive heart failure in high-risk patients.
                    [DatePublished] => 2008-11-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 140669
                    [Title] => Cardiovascular study underway
                    [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Association’s annual meeting its extensive cardiovascular trial program ONTARGET. 


The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan.

Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies.
[DatePublished] => 2001-11-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 134000 [Title] => Study centers in 40 countries involved in heart pr [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.
[DatePublished] => 2001-09-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with